DELRUS, a major medical device distributor in Russia, has inked a distribution deal with MagForce, a medical technology firm focusing on nanomedicine in oncology, to market MagForce's NanoTherm therapy in the regions, including the Russian Federation, Republic of Uzbekistan, Republic of Tajikistan, Ukraine, Republic of Kazakhstan, Republic of Kyrgyzstan and Belarus Republic.
Besides marketing the NanoTherm therapy, DELRUS has also been entrusted with the task to get marketing authorization for the therapy for brain tumor treatment in the aforementioned nations. Other tumor indications will also come under the scope of the deal upon getting an approval for the therapy as in the European Union (EU).
The NanoTherm therapy is MagForce's proprietary technology that facilitates the local treatment of solid tumors by generating intratumoral heat through magnetic nanoparticle activation. NanoTherm, NanoActivator, and NanoPlan are the therapy’s components and have obtained EU-wide regulatory approval to be used as medical devices to treat brain tumors.
MagForce’s Founder and Chief Scientific Officer, Dr. Andreas Jordan stated that the company is happy to sign the distribution deal with DELRUS to market its NanoTherm therapy in Russia and other CIS nations. DELRUS distributes products of major medical device manufacturers such as Fresenius Kabi, GE, Nihon Kohden, Johnson & Johnson, Stryker, Terumo and Haemonetics. DELRUS’ broad service and distribution network will be helpful in commercializing this nanotechnology in these countries.
DELRUS’ President, July Magadeev commented that the company anticipates an opportunity to market nanomedicine in oncology in Russia and other CIS nations.
Source: http://www.magforce.de